INCY Incyte Genomics Inc
XNAS
115.90
Delayed
Stock quote, options chain, IV rank, technicals, AI analysis, and institutional ownership. Iron condor setups Expected move IV rank history Fibonacci levels Insider trading
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.
INCY
$115.90
—
Key stats
$115.90
- 52-Week Range
- $84.02 – $132.60
- YTD
- +14.28%
- IV Rank (30D)
- 88.01
- Straddle Price
- $13.15
- P/C Vol Ratio
- 1.85
- Market Cap
- $23.7B
- Open
- $116.75
- Day Range
- $115.12 – $116.86
- Volume
- 347,262
- Prev Close
- $116.93
Fair Value
+50.0% vs price
A blended fair-value estimate combining up to six valuation methods. Each method is weighted by how well it fits the company — DCF down-weights for unprofitable names; DDM only fires for steady dividend payers; comparables down-weight when peer multiples disagree.
- DCF (quality-aware) — projects free cash flow with a horizon that scales to business quality. True compounders (quality 6/6) get 10 years explicit + 10 years fade before terminal; cyclical/struggling names (quality 0-1) get a 5-year terminal cliff. Quality is scored from ROE, gross margin, growth, FCF margin, debt load, and FCF consistency — the same factors that drive market premium for compounders.
- Market-Implied Growth (in Model Inputs) — reverse-DCF that answers "what growth rate is the market pricing in?". Lets you sanity-check the deviation: if implied growth is plausible for the business, the model's bearish flag may be wrong; if implausible, the market may be over-extrapolating.
- DDM (Gordon Growth Dividend Model) — values the stream of future dividends. Only used when trailing yield ≥ 2% and dividend payments are stable — below that the dividend is a token payout and Gordon (which values only the dividend stream) systematically underprices growth names, so those route to DCF + comparables + market anchor instead.
- P/E, EV/EBITDA, P/B, P/S — applies the peer-group median multiple to this company's per-share metric. Peers come from the same set as the "Related symbols" card. Earnings/sales metrics are forward-tilted by the company's recent revenue growth (capped at 25%) so they're comparable to peers' growth-embedded multiples — mimics how analysts use NTM rather than TTM. Per-multiple weights are biased by company quality (e.g. P/B down-weighted for asset-light tech).
- Market Anchor (SMA50) — the 50-day moving average, weighted by recent trading-range stability (tighter Bollinger bands → higher weight). Captures information fundamentals miss (forward consensus, sentiment, supply/demand) — but only when recent trading is steady enough that the market has converged on a view. During wild breakouts or breakdowns the anchor's weight collapses.
- Options Expected (B-L 30d) — the risk-neutral expected stock price at 30-day options expiration, derived from the full implied-volatility surface via Breeden-Litzenberger (second derivative of call price wrt strike → implied PDF, then E[S_T]). Forward-looking, captures all options-implied information (smile, skew, term structure) in one number. Weighted by chain liquidity. SP500-only at present (pre-computed daily). Backtest evidence: adds modest alpha across most bucket × holding combos.
- Blended value — weighted average. Confidence reflects how many methods fired and how tight peer dispersion is.
- Deviation pill — green when blended FV ≥ 10% above current price (undervalued); red when ≥ 10% below; grey otherwise.
| 10-yr Treasury (rf) | 5.12% |
| Beta vs SPY | 0.62 |
| Cost of Equity (CAPM) | 8.23% (VRP-adj) |
| WACC | 8.27% |
| Volatility Risk Premium | +28.0pp (IV − HV30) |
| Effective Tax Rate | 18.0% |
| Rev. Growth (YoY, DCF input) | +22.6% |
| DCF Horizon | 15 years explicit + fade |
| Forward Tilt (NTM/TTM) | ×1.10 (applied to P/E, EV/EBITDA, P/S) |
| Free Cash Flow (TTM) | $1.9B |
| Return on Equity (TTM) | 25.4% |
| Book / Price | 26.6% |
| Gross Margin (TTM) | 92.6% |
| FCF Margin (TTM) | 33.0% |
| Debt / Equity | 0.00 |
| Quality Score | 6/6 — compounder (15y DCF) |
| Market-Implied Growth | -5.0% (reverse-DCF on current price) |
| SMA 50 | $121.36 (Market Anchor value) |
| SMA 20 / Bollinger Mid | $115.48 |
| Bollinger Width / SMA20 | 13.2% (drives anchor stability) |
| Net Debt | $-4.0B |
| Market Cap | $24B |
Peers used for multiples: AMGN, GILD, LLY, MRNA, NVDA, REGN, UTHR, VRTX
Blended Fair Value
$291.90
Deviation
+50.0%
| Method | Implied Price | Weight | Detail |
|---|---|---|---|
| DCF | $761.86 | 20% | |
| DDM (Gordon) | n/a | 0% | |
| Peer P/E | $237.03 | 9% | median 27.4× · 6 peers |
| Peer EV/EBITDA | $277.71 | 9% | median 24.7× · 7 peers |
| Peer P/B | $475.46 | 2% | median 15.3× · 8 peers |
| Peer P/S | $285.46 | 6% | median 9.1× · 8 peers |
| Market Anchor (SMA50) | $121.36 | 34% | stability 84% (BB-width) |
| Options Expected (B-L 30d) | $116.69 | 19% | 19 strikes · skew +0.46 |
As of 2026-10-23 · updated
Related
About
- Industry (SIC)
- SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH (8731) · industry map
- Exchange
- XNAS
- Market Cap
- $23.7B
- Employees
- 2,844
- List Date
- 1993-11-03
- CIK
- 0000879169
- Next Earnings
- 2026-10-29 (Pre-Market)
- EPS Forecast
- ($3.78) (5 est.)
- Headquarters
- Wilmington, DE
- Homepage
- https://www.incyte.com
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes…
Summary
—
composite
—
No summary data available for this symbol yet.
Each spoke is this symbol's rank within its sector (0–100; the dotted ring marks the sector median at 50). Higher is more constructive for a long. One spoke — News sentiment — is an absolute reading, not a sector rank. Grayed spokes have no data. A fuller shape is a summary, not a recommendation.
Chart
Seasonality
| Month | '21 | '22 | '23 | '24 | '25 | '26 | Avg |
|---|---|---|---|---|---|---|---|
| Jan | 3.82% | 0.49% | 7.03% | -10.21% | 6.66% | -1.33% | 1.08% |
| Feb | -13.48% | -9.16% | -10.07% | -1.35% | -0.33% | -1.36% | -5.96% |
| Mar | 2.06% | 15.60% | -7.14% | -3.52% | -13.82% | -5.92% | -2.12% |
| Apr | 2.86% | -6.23% | 2.41% | -8.10% | 2.87% | 1.03% | -0.86% |
| May | -2.03% | -0.21% | -18.30% | 9.16% | 4.88% | -0.18% | -1.11% |
| Jun | 1.50% | 1.32% | 1.20% | 3.10% | 4.27% | 18.59% | 5.00% |
| Jul | -7.94% | 0.01% | 2.64% | 6.90% | 8.96% | 4.71% | 2.55% |
| Aug | -2.52% | -9.01% | 1.32% | 1.92% | 11.93% | 4.04% | 1.28% |
| Sep | -10.71% | -6.60% | -10.70% | -0.32% | -1.36% | -2.93% | -5.44% |
| Oct | -1.80% | 8.01% | -7.11% | 8.90% | 7.82% | -1.08%* | 2.46% |
| Nov | -2.35% | 3.53% | -0.06% | -2.02% | 2.85% | -- | 0.39% |
| Dec | 12.99% | -0.45% | 16.23% | -5.69% | -3.20% | -- | 3.98% |
| Total | -18.59% | -5.34% | -24.16% | -3.40% | 33.09% | 14.55% | -0.64% |
Technical Indicators
Quick-reference for reading the values below. Indicators combine to confirm a view — no single one is a trade signal on its own.
Trend Indicators
- SMA 20 / 50 / 200 — price above = uptrend, below = downtrend. SMA 50 crossing SMA 200 is the golden/death cross.
- EMA 12 / 26 — faster-reacting averages; 12 above 26 is short-term bullish.
- MACD — bullish when MACD > signal (green badge), bearish when below. Divergence from price often precedes reversals.
- ADX (14) — trend strength regardless of direction. <20 range, 20–25 weak trend, 25–50 trend, >50 strong trend.
- +DI / −DI — +DI > −DI favors bulls; the reverse favors bears. Read alongside ADX.
Momentum Oscillators
- RSI (14) — <30 oversold, >70 overbought. 40–60 is neutral; trending names can stay extreme.
- Stochastic %K / %D — <20 oversold, >80 overbought. %K crossing %D is an early momentum signal.
- Williams %R — inverted scale: <−80 oversold, >−20 overbought.
Oscillators work best in range-bound markets; in strong trends they give premature reversal signals.
Volume & Volatility
- Bollinger Bands — price at upper band = overbought, lower = oversold. Narrow bands (squeeze) often precede expansion.
- OBV — cumulative volume; rising OBV confirms uptrend, falling OBV confirms downtrend. Divergence from price is a warning.
- Vol SMA 20 / Vol ROC — today's volume vs. 20-day average. Positive ROC with price move = conviction.
- ATR / True Range — average daily $ move; sizing and stop-loss reference.
- HV 20 / 30 / 60 — realized (historical) volatility. Compare to IV on the options cards: IV > HV = rich premium.
Confluence matters: trend + momentum + volume agreeing carries far more weight than any single indicator. For how these feed the spread scanner score, see the algorithm docs →
Trend Indicators
SMA 20: $115.08
SMA 50: $121.27
SMA 200: $107.79
Current: $115.90
EMA 12: $114.81
EMA 26: $116.62
MACD: -1.8136 | Signal: 0.6383
BEARISH
ADX (14): 21.50
WEAK TREND
+DI: 18.08
−DI: 20.14
Momentum Oscillators
RSI (14): 48.18
NEUTRAL
Stoch %K: 81.36
Stoch %D: 69.61
Williams %R: -13.53
Volume & Volatility
BB Upper: $122.98
BB Lower: $107.19
NEUTRAL
OBV: 83,884,005
Vol SMA 20: 1,701,275
Vol ROC: -69.59%
ATR: $3.23
True Range: $1.81
HV 20: 29.2%
HV 30: 27.6%
HV 60: 26.7%
Data Summary
Data Points: 500
Last Updated:
Date Range: 2024-10-24T00:00:00 – 2026-10-22T00:00:00
AI Analysis
LLM Stock Analysis Report
SYMBOL: INCY
Executive Summary Confidence Level: 8/10 (BULLISH)
Key Drivers:
- Strong momentum signals from MACD and RSI
- Positive recent news headlines on rare bleeding disorder drug and pipeline updates
- Low volatility, indicating less risk relative to market
Primary Risks:
- Overbought conditions from RSI and Stochastic Oscillators
- Negative sentiment from put/call volume ratio and options market expectation
Investment Thesis: Incy's strong momentum and positive news flow make it a promising investment opportunity. However, caution is advised due to overbought conditions and bearish options market expectations.
Recent News Sentiment Impact: The recent positive news headlines have contributed to the stock's upward momentum, with sentiment analysis indicating a 75% positive tone.
Technical Analysis
- Trend Direction: Short-term: Bullish (above SMA 20); Medium-term: Bullish (above SMA 50); Long-term: Neutral
- Support/Resistance Levels: Key levels include $99.41 (SMA 20), $97.92 (SMA 50), and $96.59 (SMA 200)
- Momentum Signals:
- RSI interpretation: Overbought (>70) at 53.77
- MACD signal: Bullish momentum with a crossover above the signal line
- Bollinger Bands position: Neutral, indicating a pause in the upward trend
- Volume Analysis: Volume trends and institutional interest signals indicate a moderate increase in volume, suggesting increasing investor participation.
News & Sentiment Analysis
- Recent Headlines Summary: Positive news on rare bleeding disorder drug and pipeline updates.
- Sentiment Assessment: Aggregate news sentiment is 75% positive.
- Catalyst Identification: Upcoming clinical trial results and regulatory approvals for the rare bleeding disorder drug.
- Market Narrative: The recent news flow aligns with the bullish technical signals, reinforcing the market's optimism.
Risk & Volatility Assessment
- Beta Interpretation: Low risk relative to market (beta 0.62).
- Volatility Regime: Current volatility is low compared to historical levels.
- Options Market Signals: IV rank indicates low volatility, with a current IV of 50.5%.
- Downside Protection: Support levels and risk management considerations suggest a potential pullback to $99.41 (SMA 20).
Market Context & Positioning
- Sector Performance: Incyte's performance is strong relative to its sector.
- Institutional Activity: Moderate institutional interest, with increasing volume participation.
- Correlation Analysis: The stock moves relatively less than the market, indicating a low correlation.
- Relative Valuation: The stock is positioned within a trading range, with room for further upside.
Key Levels & Action Items
- Critical Price Levels: Support at $99.41 (SMA 20) and resistance at $107.89 (Upper Bollinger Band).
- Breakout/Breakdown Levels: A potential breakout above $107.89 or a breakdown below $96.59 could trigger significant moves.
- Time-Sensitive Catalysts: Upcoming clinical trial results and regulatory approvals for the rare bleeding disorder drug.
- Risk Management: Consider setting stop-loss levels at $99.41 to manage risk, with a target profit level at $107.89.
Please note that this report is intended as a general analysis and should not be taken as investment advice.
Generated
News
All INCY news →
Earnings History
18 of 23 under expected move
Avg Expected Move
7.81%
Avg Actual Move
4.64%
| Earnings Date | Timing | Expected Move | Actual Move | Ratio | Outcome |
|---|---|---|---|---|---|
| 2021-02-09 | Pre-Market | 6.69% | 4.44% | 0.66x | Within |
| 2021-05-04 | Pre-Market | 6.64% | 5.25% | 0.79x | Within |
| 2021-08-03 | Pre-Market | 6.44% | 0.66% | 0.10x | Within |
| 2021-11-02 | Pre-Market | 9.13% | 8.46% | 0.93x | Within |
| 2022-02-08 | Pre-Market | 7.16% | 4.47% | 0.62x | Within |
| 2022-05-03 | Pre-Market | 8.01% | 1.49% | 0.19x | Within |
| 2022-08-02 | Pre-Market | 8.14% | 6.23% | 0.77x | Within |
| 2022-11-01 | Pre-Market | 4.57% | 3.51% | 0.77x | Within |
| 2023-02-07 | Pre-Market | 5.70% | 4.03% | 0.71x | Within |
| 2023-05-02 | Pre-Market | 4.61% | 7.14% | 1.55x | Exceeded |
| 2023-08-01 | Pre-Market | 6.75% | 0.05% | 0.01x | Within |
| 2023-10-31 | Pre-Market | 8.07% | 3.39% | 0.42x | Within |
| 2024-02-13 | Pre-Market | 10.86% | 2.59% | 0.24x | Within |
| 2024-04-30 | Pre-Market | 8.56% | 0.97% | 0.11x | Within |
| 2024-07-30 | Pre-Market | 7.65% | 1.17% | 0.15x | Within |
| 2024-10-29 | Pre-Market | 7.57% | 12.04% | 1.59x | Exceeded |
| 2025-02-10 | Pre-Market | 10.93% | 7.86% | 0.72x | Within |
| 2025-04-29 | Pre-Market | 8.61% | 1.53% | 0.18x | Within |
| 2025-07-29 | Pre-Market | 7.63% | 10.28% | 1.35x | Exceeded |
| 2025-10-28 | Pre-Market | 11.66% | 1.54% | 0.13x | Within |
| 2026-02-10 | Pre-Market | 7.25% | 8.24% | 1.14x | Exceeded |
| 2026-04-28 | Pre-Market | 8.31% | 2.12% | 0.26x | Within |
| 2026-07-28 | Pre-Market | 8.66% | 9.30% | 1.07x | Exceeded |
Earnings calendar: this week’s reports with expected vs actual moves →
INCY Options Activity & IV Rank
INCY IV rank history, 52-week IV rank and IV percentile →
Volatility Metrics
Current IV: 50.2%
7-DTE IV: —
Expected Move: $13.15
7-DTE Move: $13.15
Days to Exp: 28 (2026-11-20)
Options Flow
Call Volume: 94
Put Volume: 174
P/C Volume: 1.851
BEARISH
Call OI: 2,038
Put OI: 2,741
P/C OI: 1.345
Total OI: 4,779
ATM Options Pricing
ATM Call: $7.05
ATM Put: $6.10
Call %: 6.1%
Put %: 5.3%
Chain Summary
Chain Volume: 1,613
Chain OI: 28,010
Last Updated: 10/23/2026
Spread Scanner GPU
Each spread is ranked by a composite score built in three stages. Full documentation →
Stage 1 — Base Score (GPU scanner)
score = P(profit) × (credit / spread_width)
P(profit) from short leg delta (1 − |delta|), penalised above 85%. Credit uses mid-price to handle illiquid chains fairly.
Stage 2 — Skew Adjustment (±25% cap)
RR and BF (30-delta) from the persisted per-symbol skew snapshot — wing strikes picked by real greeks.delta, not a moneyness proxy. Put skew boosts bull puts, penalises bear calls. High butterfly boosts iron condors. Calendars are skew-neutral.
Stage 3 — Technical Overlay (±50% cap, 5 groups)
Group 1 · Directional Bias (±0.25)
- RSI <40 bullish / >60 bearish
- MACD crossover + histogram trend
- Price vs SMA 50 & SMA 200
Group 2 · Momentum (±0.10)
- Stochastic %K <20 / >80
- Williams %R <−80 / >−20
Group 3 · Volatility (up to −0.25 / +0.15)
- Blended ATR + straddle expected-move penalty
- Bollinger Band signal (+ counter-trend penalty)
- BB width — vol contraction boost for ICs
Group 4 · IV Regime (±0.15)
- IV rank ≥ 75 → strong boost for credit spreads
- IV rank < 25 → penalty (selling cheap vol)
Group 5 · Liquidity (penalty up to −0.10)
- Min open interest across all legs
- OI < 100 → −0.10 · OI < 500 → −0.05
score = base_score × skew_multiplier × tech_multiplier
Both multipliers are shown per spread. Beta is informational only — ATR already captures realized vol. Full algorithm documentation →
Enter a ticker to scan for optimal spread opportunities.
Evaluates all bull put, bear call, iron condor, and calendar spread combinations using GPU-accelerated analysis.
Dealer Positioning
LOW γ vs HISTORY
Estimated net dealer gamma is at the 7th percentile of this name's own daily history, near the low end of its range. This describes current positioning; it is not a forecast or a trading signal.
Gamma percentile
7%
vs own history
GEX tilt
-0.28
OI-weighted, today
Vanna tilt
+0.51
δ-sensitivity to IV
Charm tilt
-0.47
δ-decay vs time
Vanna tilt +0.51: the estimated dealer exposure leans positive, so the modeled hedge would shift noticeably if implied volatility changed.
Charm tilt -0.47: the estimated dealer exposure leans negative, so the modeled hedge would shift noticeably as time passes and options approach expiry.
? What is this?
· 41 ATM contracts, 16k total OI
Net dealer gamma is an estimate of the aggregate gamma held by options market makers across this name's option chain, weighted by open interest. Dealer positions aren't public, so it uses a standard simplifying assumption: dealers are treated as long the calls and short the puts that are open. Actual dealer books can differ.
Gamma percentile ranks today's estimate against this name's own daily history, from 0% (the lowest reading on record) to 100% (the highest). Raw gamma scales with how much open interest a chain carries, so it isn't comparable across names; the percentile is. The badge marks the bottom 20% as low and the top 20% as high.
Tilts run from −1 to +1 and show how lopsided the estimated dealer exposure is. GEX tilt compares call gamma with put gamma. Vanna tilt describes how the hedge would shift if implied volatility changed, and charm tilt how it would shift with the passage of time.
This card describes estimated positioning and where it sits historically. It is not a forecast of price direction or volatility and not a trading signal. Market-wide view: Dealer positioning screener.
Skew (Wing IV − ATM IV)
DTE:
Wing Δ:
Wing vs ATM
IV(put wing) − IV(ATM), in vol pointsHow much the OTM put trades above (or below) the at-the-money strike. Measures the height of the put-side tail relative to ATM — i.e. how expensive crash insurance is on this name.
- Positive (typical) — wing IV > ATM IV. Standard equity put skew: portfolios bid up crash protection, so OTM puts trade richer than ATM.
- Near zero or negative (unusual) — wing IV ≤ ATM IV. Flat or inverted put side. Common when there's no fear demand, in tightly mean-reverting names, or right after an earnings catalyst clears.
- Percentile vs own 3-yr history: high = wings rich (good time to sell wing premium); low = wings cheap (good time to buy protection).
- Not directional — high or low wings don't predict up or down moves. It's a price tag on tail insurance, not a forecast.
Risk Reversal
IV(call wing) − IV(put wing), equal delta on each sideWhich side of the smile is the market paying up for? Measures the tilt of the surface — call skew vs put skew at matched deltas.
- Negative (typical) — puts richer than calls. Standard equity behavior: hedging demand makes puts carry a premium. Most large-caps sit in the −1 to −5 vol-point range.
- Strongly negative (< −5 pts) — heavy downside hedging, elevated fear, or an upcoming catalyst (earnings, FDA, macro event). Worth flagging.
- Positive — calls richer than puts. Unusual for equities; signals bullish momentum, short-squeeze positioning, or takeover/M&A speculation.
- Near zero — symmetric surface. Market sees roughly equal up/down risk. Rare for large-caps; more common in commodities and FX.
Reading them together
Wing-vs-ATM tells you how expensive the tails are. Risk Reversal tells you which side is favored. Combined:
- High wing percentile + deeply negative RR → strong put bid; stress or major event priced in. Owning protection costs a premium; selling put premium is dangerous.
- Low wing percentile + near-zero RR → complacency; insurance cheap and balanced. Good environment to add cheap downside hedges.
- Positive RR + elevated wings → call-side fear-of-missing-out; common in squeeze setups. Upside calls expensive, downside puts not bid.
14 DTE / 10d
—
—
pts
EXTREME
No data
30 DTE / 10d
58%
+6.6
pts
EXTREME
ATM 51.1% / Wing 57.7%
Extreme reading.
Historically these have been contrarian — on the small set of observed earnings-day cases, large negative wing-vs-ATM gaps (calls pricing much richer than puts at the same delta) preceded sharp drops in the underlying within 1-12 days. Not financial advice and the dataset is small.
Percentile is the rank of today's reading within ~3 years of this symbol's own history. High percentile = wings are rich relative to history; not a directional signal. Skew is read off the chain in real time, not from CBOE SKEW.
Volatility Surface
Enter a ticker to render the implied volatility surface.
Volatility Smile
Enter a ticker to render the implied volatility smile.
IV Rank (7 DTE)
IV Rank (30 DTE)88.0HighOct 23
Straddle Price (30 DTE)$13.15Oct 23
Beta Analysis
Risk Metrics
Beta: 0.3882
Alpha: 26.54%
Correlation: 0.1468
R-Squared: 2.2%
Stock Volatility: 33.7%
Market Volatility: 12.7%
Analysis Details
Benchmark: SPY
Data Points: 251
Period: 252 trading days
Data Points: 251
Period: 252 trading days
Interpretation:
Low volatility - stock moves less than market
Low volatility - stock moves less than market
Beta & Alpha Over Time
Notable investors who own INCY
5 of 37 tracked investors
| Investor | Value | Share of their portfolio | Rank | Q/Q shares | Source |
|---|---|---|---|---|---|
| Renaissance Technologies Hedge fund Jim Simons | $398.1M | #27 of 3138 | -3.8% | 13F | |
| Bridgewater Associates Hedge fund Ray Dalio | $19.1M | #215 of 997 | +29.1% | 13F | |
| Citadel Hedge fund Ken Griffin | $16.3M | #1272 of 6285 | +191.2% | 13F | |
| Millennium Management Hedge fund Izzy Englander | $9.4M | #1616 of 3716 | -52.1% | 13F | |
| Rockefeller Capital Management Family office Rockefeller family | $4.3M | #1033 of 4729 | +2.6% | 13F |
Hedge funds, activists, holding companies and family offices we track, from their latest 13F (quarter-end value) and Form 4 filings in the last 3 years. Family offices · all institutions
INCY Institutional Ownership (13F)
Latest filings — 2026-09-30
? 13F Guide
Diluted shares outstanding: 204,293,750 (as of 2026-06-30)
Institutional managers with $100M+ AUM file Form 13F-HR quarterly, due 45 days after quarter end. Holdings are reported gross at quarter-end market value — they are a snapshot, not a real-time position.
- Shares — long equity positions in this name, aggregated across share classes.
- Calls / Puts — notional value of long call / put exposure where this ticker is the underlying.
- % of Float — holder's reported shares divided by the latest diluted shares outstanding. Sums above 100% indicate large custodian / prime broker positions where the same shares are reported by multiple filers.
- Custodian badge — filers with more than 5,000 holdings are typically broker-dealers / custodians reporting customer-held shares, not active managers.
Each filer is counted once at its latest 13F-HR filing. New filings are ingested on a weekly cadence.
14 filers$61.19M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | Susquehanna International Group, LLP Custodian | $13.27M | 21.69% | 2026-06-30 |
| 2 | Citadel Advisors LLC Custodian | $11.61M | 18.97% | 2026-06-30 |
| 3 | Millennium Management LLC Custodian | $11.38M | 18.60% | 2026-06-30 |
| 4 | PEAK6 LLC | $8.29M | 13.54% | 2026-06-30 |
| 5 | Jane Street Group, LLC Custodian | $7.98M | 13.04% | 2026-06-30 |
| 6 | TUDOR INVESTMENT CORP ET AL | $3.09M | 5.06% | 2026-06-30 |
| 7 | Walleye Capital LLC | $1.77M | 2.89% | 2026-06-30 |
| 8 | Wolverine Trading, LLC Custodian | $1.53M | 2.50% | 2025-09-30 |
| 9 | BNP Paribas Financial Markets Custodian | $1.25M | 2.04% | 2026-06-30 |
| 10 | HUB Investment Partners, LLC | $385.42K | 0.63% | 2026-06-30 |
| 11 | D. E. Shaw & Co., Inc. Custodian | $362.75K | 0.59% | 2026-06-30 |
| 12 | Walleye Trading LLC | $158.70K | 0.26% | 2026-06-30 |
| 13 | Concurrent Investment Advisors, LLC | $60.67K | 0.10% | 2026-09-30 |
| 14 | Raiffeisen Bank International AG | $56.68K | 0.09% | 2026-06-30 |
9 filers$33.80M notional
| # | Filer | Notional Value | % of Total | Period |
|---|---|---|---|---|
| 1 | DIADEMA PARTNERS LP | $11.95M | 35.35% | 2026-06-30 |
| 2 | Susquehanna International Group, LLP Custodian | $11.26M | 33.30% | 2026-06-30 |
| 3 | Citadel Advisors LLC Custodian | $5.91M | 17.47% | 2026-06-30 |
| 4 | Jane Street Group, LLC Custodian | $2.64M | 7.81% | 2026-06-30 |
| 5 | Wolverine Trading, LLC Custodian | $1.07M | 3.15% | 2025-09-30 |
| 6 | Walleye Capital LLC | $487.45K | 1.44% | 2026-06-30 |
| 7 | Walleye Trading LLC | $204.05K | 0.60% | 2026-06-30 |
| 8 | Persistent Asset Partners Ltd | $159.04K | 0.47% | 2026-06-30 |
| 9 | Twin Tree Management, LP | $136.03K | 0.40% | 2026-06-30 |
INCY Insider Trading (Form 4)
Latest: 2026-10-19Form 4 filings — insider beneficial-ownership changes by officers, directors, and 10%+ holders. Filed within 2 business days of transaction.
| Filed | Reporter | Role | Action | Shares | Avg Price | Net $ | Link |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | Pablo J Cagnoni | President, Global Head of R&D | Mixed | — | $89.24 | -$124.0K | EDGAR |
| 2026-10-05 | Lee Heeson | EVP, Head of Incyte Intl | Tax (F) | −463 | $117.14 | -$54.2K | EDGAR |
| 2026-10-02 | Paul J Clancy | Director | Award (A) | +203 | $121.35 | $24.6K | EDGAR |
| 2026-10-02 | Edmund Harrigan | Director | Award (A) | +206 | $121.35 | $25.0K | EDGAR |
| 2026-10-02 | Baker Bros. Advisors (GP) LLC | Director | Award (A) | +3,864 | — | EDGAR | |
| 2026-09-24 | David H Gardner | EVP, Chief Strategy Officer | Tax (F) | −920 | $126.93 | -$116.8K | EDGAR |
| 2026-09-17 | Pablo J Cagnoni | President, Global Head of R&D | Mixed | — | $93.44 | -$1.26M | EDGAR |
| 2026-08-27 | Ramitpal K Basi | EVP, Human Resources | Tax (F) | −504 | $129.72 | -$65.4K | EDGAR |
| 2026-08-20 | Pablo J Cagnoni | President, Global Head of R&D | Sell (S) | −10,801 | $125.56 | -$1.36M | EDGAR |
| 2026-08-14 | Pablo J Cagnoni | President, Global Head of R&D | Sell (S) | −10,803 | $120.04 | -$1.30M | EDGAR |
| 2026-08-07 | Pablo J Cagnoni | President, Global Head of R&D | Sell (S) | −10,640 | $122.69 | -$1.31M | EDGAR |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | Mixed | — | $115.23 | -$38.7K | EDGAR |
| 2026-08-07 | Patrick A Mayes | EVP & Chief Scientific Officer | Mixed | — | $115.23 | -$38.7K | EDGAR |
| 2026-08-07 | Pablo J Cagnoni | President, Global Head of R&D | Sell (S) | −10,640 | $122.69 | -$1.31M | EDGAR |
| 2026-08-04 | Pablo J Cagnoni | President, Global Head of R&D | Sell (S) | −15,888 | $119.70 | -$1.90M | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (described in filing footnote — typically 401(k), trust, inheritance) · W = will/inheritance. Only P / S codes carry directional signal.
INCY Insider Holdings
32 insiders · @ $115.90
Officers, directors, and 10%+ owners who have filed a Form 4 in the past two years, ranked by current disclosed exposure (shares × today's price). Shares are direct + indirect (via trusts / LLCs / spouse). Excludes unvested RSU and option grants — those aren't beneficially owned until vest.
| # | Insider | Role | Shares | Disclosed Exposure | Lifetime OM Net | Filings | Last Filed |
|---|---|---|---|---|---|---|---|
| 1 | 667, L.P. | Director | 28,482,491 | $3.30B | $0 | 11 | 2026-05-11 |
| 2 | Baker Bros. Advisors (GP) LLC | Director | 3,116,593 | $361.21M | $1.13B | 13 | 2026-10-02 |
| 3 | Felix Baker | Director | 3,115,871 | $361.13M | -$15.68M | 30 | 2026-06-10 |
| 4 | Baker Brothers Life Sciences LP | Director | 3,098,808 | $359.15M | $390.15M | 15 | 2026-01-05 |
| 5 | Herve Hoppenot | Special Advisor to the CEO | 352,703 | $40.88M | -$48.93M | 50 | 2025-12-10 |
| 6 | BAKER BROS. ADVISORS LP | Director | 314,600 | $36.46M | $1.09B | 11 | 2025-04-02 |
| 7 | Julian Baker | Director | 314,600 | $36.46M | $1.09B | 79 | 2026-07-02 |
| 8 | Pablo J Cagnoni | President, Global Head of R&D | 185,842 | $21.54M | -$15.71M | 23 | 2026-10-19 |
| 9 | William Meury | Chief Executive Officer | 183,129 | $21.22M | $0 | 5 | 2026-07-20 |
| 10 | Christiana Stamoulis | EVP & Chief Financial Officer | 114,652 | $13.29M | $0 | 26 | 2025-07-16 |
Lifetime OM Net = signed sum of open-market buys (P) and sells (S) over their career; excludes grants, tax withholdings, and dispositions to issuer. A large negative number is normal for long-tenured executives — they've sold compensation grants over many years.
INCY Board & Officers
As of SEC filings through Oct 19, 2026Directors 13
- Julian Baker · on file since Apr 2006
- Felix Baker · on file since Jan 2008
- Baker Bros. Advisors LP (entity) · since Apr 12, 2012
- 667, L.p. (entity) · since Jun 11, 2013
- Baker Brothers Life Sciences LP (entity) · since Jun 11, 2013
- Baker Bros. Advisors (GP) LLC (entity) · since Jul 1, 2013
- Jean Jacques Bienaime · since Jan 20, 2015
- Paul J Clancy · since Jan 20, 2015
- Jacqualyn A Fouse · since Nov 14, 2017
- Edmund Harrigan · since Dec 16, 2019
- Katherine A High · since Mar 26, 2020
- Otis W Brawley · since Sep 27, 2021
- William Meury · since Jun 26, 2025
Officers 16
- William Meury · Chief Executive Officer · since Jun 26, 2025
- Pablo J Cagnoni · President, Global Head of R&D · listed since Apr 2026
- Suketu Upadhyay · EVP & Chief Financial Officer · since May 4, 2026
- Patrick A Mayes · EVP & Chief Scientific Officer · since Jul 21, 2025
- David H Gardner · EVP, Chief Strategy Officer · since Sep 22, 2025
- Richard A. Hoffman · EVP & General Counsel · since Dec 1, 2025
- Paula J Swain · EVP, Human Resources · on file since 2006
- Barry P Flannelly · EVP & General Manager US · listed since Jan 2016
- Michael James Morrissey · EVP, Head of Tech. Operations · since Jun 19, 2019
- Vijay K Iyengar · EVP, Gmapps · listed since Jul 2022
- Matteo Trotta · EVP, GM, Dermatology US · since Mar 25, 2024
- Lee Heeson · EVP, Head of Incyte Intl · since Oct 1, 2024
- Ramitpal K Basi · EVP, Human Resources · since Aug 25, 2025
- Mohamed Khairie Issa · EVP, Head of U.S. Commercial · listed since Jul 2026
- Thomas Tray · Principal Accounting Officer · since Mar 11, 2022
- Steven H Stein · CMO & Head of Late-Stage Dev. · listed since Apr 2026
10% owners 6
- 667, L.p. (entity) · on file since Jun 2013
- Baker Bros. Advisors (GP) LLC (entity) · since Jul 1, 2013
- Baker Bros. Advisors LP (entity) · since Apr 12, 2012
- Baker Brothers Life Sciences LP (entity) · on file since Jun 2013
- Felix Baker · on file since Jan 2008
- Julian Baker · listed since Dec 2007
Changes in the last 10 years (37)
| Jul 16, 2026 | Mohamed Khairie Issa listed as EVP, Head of U.S. Commercial (previously EVP, Head of US Oncology) in SEC filings |
| May 4, 2026 | Suketu Upadhyay became EVP & Chief Financial Officer |
| Apr 17, 2026 | Steven H Stein listed as CMO & Head of Late-Stage Dev. (previously EVP & Chief Medical Officer) in SEC filings |
| Apr 17, 2026 | Pablo J Cagnoni listed as President, Global Head of R&D (previously President, R&D) in SEC filings |
| Mar 26, 2026 | The company announced the departure of Susanne Schaffert from the board in an SEC filing |
| Dec 10, 2025 | The company announced the departure of Herve Hoppenot from the board in an SEC filing |
| Dec 1, 2025 | Richard A. Hoffman became EVP & General Counsel |
| Nov 12, 2025 | Herve Hoppenot no longer listed as Special Advisor to the CEO in SEC filings |
| Sep 22, 2025 | David H Gardner became EVP, Chief Strategy Officer |
| Aug 25, 2025 | Ramitpal K Basi became EVP, Human Resources |
| Aug 4, 2025 | The company announced the departure of Christiana Stamoulis as EVP & Chief Financial Officer in an SEC filing |
| Jul 21, 2025 | Patrick A Mayes became EVP & Chief Scientific Officer |
| Jun 30, 2025 | Herve Hoppenot listed as Special Advisor to the CEO (previously Chairman / CEO) in SEC filings |
| Jun 26, 2025 | William Meury became a director |
| Jun 26, 2025 | William Meury became Chief Executive Officer |
| Jun 26, 2025 | The company announced the departure of Herve Hoppenot as President and CEO in an SEC filing |
| Jan 6, 2025 | Mohamed Khairie Issa became EVP, Head of US Oncology |
| Oct 1, 2024 | Lee Heeson became EVP, Head of Incyte Intl |
| Mar 25, 2024 | Matteo Trotta became EVP, GM, Dermatology US |
| Oct 2, 2023 | Sheila A. Denton became EVP & General Counsel |
| Sep 8, 2023 | The company announced the departure of Maria E Pasquale as EVP & General Counsel in an SEC filing |
| Jun 7, 2023 | Pablo J Cagnoni became President, R&D |
| Jan 24, 2023 | Herve Hoppenot first listed as Chairman / CEO in an SEC filing |
| Oct 1, 2022 | Susanne Schaffert became a director |
| Jul 6, 2022 | Vijay K Iyengar listed as EVP, Gmapps (previously EVP GPS, BD, & Licensing) in SEC filings |
| Apr 18, 2022 | The company announced the departure of Wendy L Dixon from the board in an SEC filing |
| Mar 11, 2022 | Thomas Tray became Principal Accounting Officer |
| Jan 10, 2022 | The company announced the departure of Paul Trower as Principal Accounting Officer in an SEC filing |
| Sep 27, 2021 | Otis W Brawley became a director |
| Mar 26, 2020 | Katherine A High became a director |
| Dec 16, 2019 | Edmund Harrigan became a director |
| Jun 19, 2019 | Michael James Morrissey became EVP, Head of Tech. Operations |
| Jun 19, 2019 | Jonathan Elliott Dickinson became EVP, General Manager, Europe |
| Feb 11, 2019 | Christiana Stamoulis became EVP & Chief Financial Officer |
| Dec 10, 2018 | Dashyant Dhanak became EVP & Chief Scientific Officer |
| Apr 9, 2018 | Maria E Pasquale became EVP & General Counsel |
| Nov 14, 2017 | Jacqualyn A Fouse became a director |
Not reported recently (10)
- Sheila A. Denton · Last reported as EVP & General Counsel in an SEC filing dated Nov 19, 2025
- Jonathan Elliott Dickinson · Last reported as EVP, General Manager, Europe in an SEC filing dated Sep 16, 2024
- Dashyant Dhanak · Last reported as EVP & Chief Scientific Officer in an SEC filing dated Jul 18, 2023
- Yao Wenqing · Last reported as EVP, Head of Discovery Chem in an SEC filing dated Jul 7, 2021
- Paul A Friedman · Last reported as a director in an SEC filing dated May 28, 2020
- Paul A Brooke · Last reported as a director in an SEC filing dated Apr 2, 2020
- 14159, L.p. · Last reported as a director in an SEC filing dated Jun 7, 2019
- Reid M Huber · Last reported as EVP, Chief Scientific Officer in an SEC filing dated Jul 18, 2018
- David W Gryska · Last reported as Executive Vice President, CFO in an SEC filing dated Jul 18, 2018
- Eric H. Siegel · Last reported as EVP, General Counsel in an SEC filing dated Sep 15, 2017
Compiled from SEC filings by the company and its directors and officers. Dates are as stated in those filings. Where no filing says when someone left, we show the last filing that listed them.
INCY Proposed Insider Sales (Form 144)
Latest: 2026-10-15
? Form 144 Guide
Last 30d:
1 filing
· $298K notice value
· Last 90d:
9 filings
· $15.0M notice value
· 2 unique filers
· 100% under 10b5-1 plans
What is Form 144? A notice of intent to sell restricted or control stock under Rule 144. Affiliates (officers, directors, 10%+ owners) and holders of restricted shares must file Form 144 when planning to sell more than 5,000 shares or $50,000 in any 3-month rolling window.
How it relates to Form 4: Form 144 is filed before the trade (up to 90 days in advance); Form 4 is filed within 2 business days after the trade executes. Not every Form 144 results in a sale — the filer may cancel or delay. Look for the corresponding Form 4 on the Insider Activity card to confirm a sale actually happened.
10b5-1 plans: Trades made under a pre-scheduled Rule 10b5-1 plan are not discretionary — they execute automatically on dates set months earlier, regardless of news. High 10b5-1 percentages mean less per-filing signal value, though cumulative selling volume still matters.
"Notice value": Aggregate market value the filer wrote into the Form 144 — i.e. the size of the planned sale, not necessarily the executed dollars. An amended notice (Form 144/A) replaces the original it amends, and cancelled notices are dropped, so neither is double-counted above. A filed value that is clearly inconsistent with the share count at the stock's price (a filer typo) shows as a dash and is left out of the totals.
Source & freshness: Sourced from public Form 144 filings. Refreshed daily; new filings typically appear here the morning after they are filed.
Top 90-day filers:
PABLO CAGNONI (6, $9.0M) · PATRICK A MAYES (3, $6.0M)
| Filed | Filer | Role | Shares | Notice Value | Planned Sale | Broker | Plan | Link |
|---|---|---|---|---|---|---|---|---|
| 2026-10-15 | PABLO CAGNONI | Officer | 2,642 | $297.8K | 2026-10-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-09-15 | PABLO CAGNONI | Officer | 23,218 | $2.80M | 2026-09-15 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-19 | PABLO CAGNONI | Officer | 10,801 | $1.36M | 2026-08-19 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-12 | PABLO CAGNONI | Officer | 10,803 | $1.30M | 2026-08-12 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-05 | PABLO CAGNONI | Officer | 10,640 | $1.31M | 2026-08-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-05 | PATRICK A MAYES | Officer | 2,207 | $273.6K | 2026-08-05 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-08-03 | PATRICK A MAYES | Officer | 6,055 | $729.2K | 2026-08-03 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-31 | PATRICK A MAYES | Officer | 41,899 | $5.01M | 2026-07-31 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-31 | PABLO CAGNONI | Officer | 15,888 | $1.90M | 2026-07-31 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
| 2026-07-16 | STEVEN STEIN | Officer | 1,877 | $215.3K | 2026-07-16 | Morgan Stanley Smith Barney LLC … | 10b5-1 | EDGAR |
Notice value is the aggregate market value the filer states they intend to sell — not a confirmed transaction. Compare to Insider Activity (Form 4) to see which planned sales actually executed. Market-wide feed: Planned sales (Form 144).
Recent SEC Filings
Latest: 2026-04-28
Current reports — material events the company must disclose within 4 business days (earnings releases, M&A, executive changes, etc.).
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-28 | 0000879169-26-000023 | EDGAR |
| 2026-03-30 | 0000879169-26-000018 | EDGAR |
| 2026-03-26 | 0000879169-26-000016 | EDGAR |
| 2026-03-06 | 0000879169-26-000013 | EDGAR |
| 2026-02-10 | 0000879169-26-000006 | EDGAR |
| 2025-12-12 | 0000879169-25-000122 | EDGAR |
| 2025-10-28 | 0000879169-25-000115 | EDGAR |
| 2025-10-03 | 0001104659-25-096632 | EDGAR |
| 2025-08-07 | 0000879169-25-000108 | EDGAR |
| 2025-07-29 | 0000879169-25-000100 | EDGAR |
Annual report — audited financial statements, MD&A, risk factors. Filed 60–90 days after fiscal year-end.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-02-10 | 0000879169-26-000010 | EDGAR |
| 2025-02-10 | 0001628280-25-004633 | EDGAR |
| 2024-02-13 | 0000879169-24-000045 | EDGAR |
| 2023-02-07 | 0000879169-23-000008 | EDGAR |
| 2022-02-08 | 0001558370-22-000902 | EDGAR |
| 2021-02-09 | 0001558370-21-000825 | EDGAR |
| 2020-02-13 | 0001558370-20-000774 | EDGAR |
| 2019-02-14 | 0001558370-19-000682 | EDGAR |
Quarterly report — unaudited financials and MD&A. Filed 40–45 days after each of the first three fiscal quarters.
| Filing Date | Accession | Link |
|---|---|---|
| 2026-04-28 | 0000879169-26-000026 | EDGAR |
| 2025-10-28 | 0000879169-25-000118 | EDGAR |
| 2025-07-29 | 0000879169-25-000103 | EDGAR |
| 2025-04-29 | 0000879169-25-000056 | EDGAR |
| 2024-10-29 | 0000879169-24-000172 | EDGAR |
| 2024-07-30 | 0000879169-24-000149 | EDGAR |
| 2024-04-30 | 0000879169-24-000077 | EDGAR |
| 2023-10-31 | 0000879169-23-000041 | EDGAR |
| 2023-08-01 | 0000879169-23-000025 | EDGAR |
| 2023-05-02 | 0000879169-23-000016 | EDGAR |
ETF Holders
338 ETFs hold INCY
25 shown · $4.04B total exposure · 0.07% AUM-weighted avg weight
| # | ETF | Provider | Weight | $ Exposure | ETF AUM | As Of |
|---|---|---|---|---|---|---|
| 1 | VTI Vanguard Morningstar Total Stock Market ETF | Vanguard | 0.03% | $664.6M | — | 2026-09-30 |
| 2 | VOO Vanguard S&P 500 ETF | Vanguard | 0.03% | $542.8M | — | 2026-09-30 |
| 3 | VB Vanguard Morningstar Small-Cap ETF | Vanguard | 0.26% | $470.6M | — | 2026-09-30 |
| 4 | VBK Vanguard Morningstar Small-Cap Growth ETF | Vanguard | 0.60% | $261.9M | — | 2026-09-30 |
| 5 | IVV iShares Core S&P 500 ETF | iShares (BlackRock) | 0.03% | $256.5M | $878.4B | 2026-10-21 |
| 6 | SPY State Street® SPDR® S&P 500® ETF Trust | SPDR (State Street) | 0.03% | $237.0M | $820.7B | 2026-10-21 |
| 7 | RSP Invesco S&P 500 Equal Weight ETF | Invesco | 0.18% | $176.7M | — | 2026-10-21 |
| 8 | IBB iShares Biotechnology ETF | iShares (BlackRock) | 1.59% | $175.3M | $10.9B | 2026-10-21 |
| 9 | XBI State Street® SPDR® S&P® Biotech ETF | SPDR (State Street) | 1.33% | $142.2M | $10.7B | 2026-10-21 |
| 10 | XLV State Street® Health Care Select Sector SPDR® ETF | SPDR (State Street) | 0.30% | $141.2M | $47.5B | 2026-10-21 |
| 11 | VFLO VictoryShares Free Cash Flow ETF | Nport | 1.74% | $135.1M | — | 2026-06-30 |
| 12 | USMV iShares MSCI USA Min Vol Factor ETF | iShares (BlackRock) | 0.42% | $100.7M | $24.3B | 2026-10-21 |
| 13 | FBT First Trust NYSE® Arca® Biotechnology Index Fund | First Trust | 3.27% | $98.5M | $3.0B | 2026-10-21 |
| 14 | IWR iShares Russell Mid-Cap ETF | iShares (BlackRock) | 0.14% | $79.9M | $57.2B | 2026-10-21 |
| 15 | COWZ Pacer US Cash Cows 100 ETF | Nport | 0.44% | $79.3M | — | 2026-04-30 |
| 16 | VHT Vanguard Health Care ETF | Vanguard | 0.29% | $63.0M | — | 2026-09-30 |
| 17 | DFAC Dimensional US Core Equity 2 ETF | Dimensional | 0.06% | $57.0M | — | 2026-10-21 |
| 18 | CALF Pacer US Small Cap Cash Cows 100 ETF | Nport | 1.55% | $53.5M | — | 2026-04-30 |
| 19 | SPYM State Street® SPDR® Portfolio S&P 500® ETF | SPDR (State Street) | 0.03% | $53.3M | $184.5B | 2026-10-21 |
| 20 | FMDE Fidelity Enhanced Mid Cap Core ETF | Fidelity | 0.60% | $51.1M | $8.6B | 2026-10-21 |
| 21 | SCHM Schwab U.S. Mid-Cap ETF | Nport | 0.30% | $43.7M | — | 2026-05-31 |
| 22 | IWD iShares Russell 1000 Value ETF | iShares (BlackRock) | 0.05% | $42.5M | $84.8B | 2026-10-21 |
| 23 | IVW iShares S&P 500 Growth ETF | iShares (BlackRock) | 0.05% | $41.2M | $75.8B | 2026-10-21 |
| 24 | GSLC Goldman Sachs ActiveBeta U.S. Large Cap Equity ETF | Goldman | 0.24% | $37.1M | $15.3B | 2026-10-21 |
| 25 | SPGP Invesco S&P 500 GARP ETF | Invesco | 1.74% | $36.4M | — | 2026-10-21 |
Fundamentals
Quarterly filings sourced from SEC 10-Q / 10-K reports. TTM tiles aggregate the most recent four quarters; bars show the last ~12 quarters oldest → newest.
Metrics
- Revenue — top-line sales. Look for consistent YoY growth; seasonal businesses need same-quarter comparisons (Q4 '24 vs Q4 '23).
- Net Income — bottom-line profit after all expenses. Can be volatile from one-time items; red bars = net loss.
- Diluted EPS — net income per share assuming options/converts are exercised. Direct input to the P/E ratio.
- Operating Cash Flow — cash generated from core operations, before capex and financing. Harder to manipulate than net income; growing OCF is a quality signal.
How to read the bars
- Sequential growth — quarter-over-quarter trend. Accelerating bars are a momentum signal.
- YoY growth — compare to the same quarter a year earlier to remove seasonality.
- Quality — OCF should roughly track Net Income over time. Large divergence (net income ≫ OCF) flags accruals risk.
- Margins — scan the bar ratios: Net Income / Revenue tells you margin trend without needing a separate chart.
TTM (trailing-twelve-month) smooths seasonality and is used for the P/E calculation. Filings appear 30–90 days after the period closes.
Trailing P/E
14.76
TTM Diluted EPS
$7.85
TTM Revenue
$5.82B
TTM Net Income
$1.61B
TTM Op. Cash Flow
$1.98B
Quarterly figures (12 quarters)
| Quarter | Period End | Revenue | Net Income | Diluted EPS | Op. Cash Flow |
|---|---|---|---|---|---|
| Q2 '26 | 2026-06-30 | $1.67B | $585.61M | $2.81 | $507.66M |
| Q1 '26 | 2026-03-31 | $1.27B | $303.33M | $1.47 | $369.35M |
| Q4 '25 | 2025-12-31 | $1.51B | $299.28M | $1.46 | $543.30M |
| Q3 '25 | 2025-09-30 | $1.37B | $424.17M | $2.11 | $559.39M |
| Q2 '25 | 2025-06-30 | $1.22B | $405.00M | $2.04 | $44.74M |
| Q1 '25 | 2025-03-31 | $1.05B | $158.20M | $0.80 | $266.07M |
| Q4 '24 | 2024-12-31 | $1.18B | $201.21M | $0.95 | $381.22M |
| Q3 '24 | 2024-09-30 | $1.14B | $106.46M | $0.54 | $310.87M |
| Q2 '24 | 2024-06-30 | $1.04B | $-444.60M | $-2.04 | $-575.56M |
| Q1 '24 | 2024-03-31 | $880.89M | $169.55M | $0.75 | $218.81M |
| Q4 '23 | 2023-12-31 | $1.01B | $201.08M | $0.89 | $147.73M |
| Q3 '23 | 2023-09-30 | $919.02M | $171.27M | $0.76 | $162.41M |
Q2 2026 • period ending 2026-06-30 • filed 2026-07-28
Valuation
Ratios derived from TTM financials and the current market price, sampled daily. History chart shows how expensive the stock is today relative to its own recent past.
Price Multiples
- P/E — price / TTM earnings. Rough market rule: 10–15 value, 15–25 market, >30 growth/premium. Negative when earnings are negative.
- P/B — price / book value. Useful for financials and asset-heavy names; meaningless for asset-light software.
- P/S — price / TTM revenue. Useful when earnings are negative or noisy (early-stage growth).
- EV/EBITDA — capital-structure-neutral. <10 cheap, 10–15 reasonable, >20 rich. Good for comparing across leverage profiles.
- EV/Sales — like P/S but accounts for debt + cash. Compare within sector.
Profitability & Yields
- ROE — return on equity. >15% strong, >25% exceptional. Caution: high leverage inflates ROE.
- ROA — return on assets. Leverage-neutral; >5% solid, >10% exceptional.
- Div Yield — annual dividend / price. Compare to 10Y Treasury; sustained yield >6% often signals distress.
- FCF Yield — free cash flow / market cap. >5% is attractive; negative means burning cash.
Balance Sheet
- Debt/Equity — leverage. <1 conservative, >2 aggressive. Sector-dependent (utilities naturally high, tech low).
- Current Ratio — short-term liquidity. >1.5 comfortable, <1 raises short-term solvency flags.
Reading the history chart
- Compare current level to the 3-year band: near the high end = relatively expensive; near the low = relatively cheap.
- Multiples expanding while earnings are flat = sentiment-driven rally.
- Multiples compressing while earnings grow = value coming from fundamentals.
P/E
14.76
P/B
3.73
P/S
4.07
EV/EBITDA
10.16
EV/Sales
3.39
ROE
25.4%
ROA
20.5%
Div Yield
0.00%
FCF Yield
8.36%
Debt/Equity
0.00
Current Ratio
—
Market Cap
$23.67B
as of 2026-10-23
Short Interest & Float
Regulatory short-interest reports publish on a bi-weekly settlement cadence; short-volume is reported daily by the trade-reporting facilities. Float is derived from insider-ownership filings.
Metric definitions
- Short Interest — total shares currently sold short as of the settlement date. Lags real time by ~8 business days.
- SI % of Float — short interest / free float. The key crowding metric.
- Days to Cover — short interest / avg daily volume. How many full trading days it would take shorts to buy back. High DTC + catalyst = squeeze fuel.
- Short Vol Ratio — today's short-sale volume / total volume. Intraday selling pressure proxy (not the same as short interest).
- Free Float — shares available for public trading (total shares minus insider / restricted).
- Float % — free float / shares outstanding. <50% = tightly held, more prone to squeezes.
How to read the signals
- SI % of Float < 5% — typical, no particular signal.
- 5–15% — elevated; watch for catalysts (earnings, guidance, macro).
- 15–30% — heavily shorted; tight-float names in this range have produced notable squeezes historically.
- >30% — extreme; borrow is likely expensive and squeeze risk is material.
- Days to Cover > 5 combined with high SI% amplifies squeeze potential.
History chart
- Trend matters more than level. Rapidly rising short interest often precedes negative catalysts or heavy hedging.
- A sudden drop in SI after a rally may indicate a squeeze in progress.
Short interest is reported mid-month and end-of-month; short volume is daily.
Short Interest
9.99M
SI % of Float
5.90%
Days to Cover
6.06
Short Vol Ratio
87.4%
Free Float
169.31M
Float %
83.5%
Short interest 2026-09-30 • Short volume 2026-10-22 • Float 2026-08-24